As per our research report, between 2022 and 2027, the global bleeding disorders treatment market is expected to increase at a CAGR of 7.98%, from USD 14.04 billion in 2022 to USD 20.61 billion by 2027.
According to the World Health Organization (WHO), the COVID-19 outbreak has affected over 38 million people worldwide, and it was declared a pandemic on March 11, 2020. The healthcare establishment has been caught off guard by this disaster. Despite the fact that several organizations are working on a vaccine, people must learn to live with the coronavirus for the time being. The coronavirus has the potential to affect the blood, as well as other organs and tissues. SARS-CoV-2 individuals have irregular blood coagulation. According to the findings, COVID-19 causes arterial and venous thrombosis by producing a distinct, prothrombotic environment. As a result, people diagnosed with the COVID-19 virus required medical attention for bleeding problems during the procedure.
Furthermore, COVID-19 has an effect on the numerous clinical trials for which it is used. Patients with bleeding issues frequently cancel their hospital visits since both facilities are focused on coronavirus cases. In addition, hospitals have stopped or postponed hemophilia replacement procedures. Aside from that, the supply chain for bleeding disorder treatments and supplies has been interrupted as a result of the pandemic’s travel ban and lockdown. As a result, amid this pandemic, bleeding disorder treatment is seeing a slow increase in demand.
The global bleeding disorder treatment market is primarily driven by year-over-year increases in the number of cases and therapeutic advancements.
Blood diseases are illnesses that affect the blood’s capacity to function normally. White blood cells, red blood cells, platelets, bone marrow, spleen, lymph nodes, and bleeding and clotting proteins are all impacted (hemostasis and thrombosis).
An increase in the number of persons with bleeding disorders is driving the market for bleeding disorder treatment. More than 1,125,000 in the world suffer from a genetic bleeding disorder, with 418,000 of them suffering from a mild version of the disease that goes unnoticed most of the time. Haemophilia is the most frequent ailment, affecting roughly 195 thousand people in 2019, whereas von Willebrand disease affects 80 thousand people. There are about 18 thousand patients with hemophilia and over 12 thousand with von Willebrand disease in the United States alone. According to the CDC, Von Willebrand disease (VWD) affects about 1% of the general population. The menstrual cycle, on the other hand, makes women more vulnerable to Von Willebrand disease. The market for bleeding problem treatment has been growing as a result of such a large number of people being treated in some form.
Many businesses and research organizations have been attempting to produce new treatments and improve existing ones in order to increase patient awareness of therapy and adoption rates. For more than 50 years, St. Jude’s physicians and experts have been researching and improving treatments for children with bleeding problems. They collaborate with a nationally certified Haemophilia Rehab Centre as well as children’s treatment facilities across the United States. In addition, researchers at Children’s Hospital of Philadelphia have developed a gene therapy vector for bleeding diseases that is theoretically safer and more effective, with a focus on sickle cell disease and beta-thalassemia. Many replacement medications now have easier delivery methods, lower immunogenicity, higher potency, and longer half-lives. For the past five years, bioengineering advancements have aided in the treatment of bleeding diseases. The bleeding problem therapy sector will flourish as a result of these breakthroughs.
Mutations in particular genes, which can be passed down through families, cause the majority of blood issues. Haemophilia A is the most frequent kind of condition in men and women, according to the National Heart, Lung, and Blood Institute. Haemophilia A affects one out of every 4,000 to 5,000 boys born worldwide, while Haemophilia B affects one out of every 20,000 males born. The global incidence of sickle cell anemia is anticipated to rise by around 30% by 2050, according to a study published in the PLOS Medicine Journal. The market for blood disease therapeutics is being driven by rising prevalence of various blood disorders and increased expenditure in research and development for advanced treatment options.
The global bleeding disorder therapy market is projected to be constrained by high treatment costs.
The high cost of treatment, on the other hand, is a major hindrance to the bleeding disorder treatment industry. Daily outpatient appointments, hospitalization, and lab investigations come at a high cost that is unattainable for middle-income nations like Asia and Africa; as a result, the development of bleeding disorders therapies in those regions has slowed. Furthermore, the bleeding disorder treatment market is hampered by a shortage of physicians in rising and developing countries, as well as an unfavorable reimbursement situation.
Avail sample market brochure of the report to evaluate report usefulness, get a copy @ https://www.marketdataforecast.com/market-reports/bleeding-disorders-treatment-market/request-sample
KEY MARKET INSIGHTS:
- The recombinant coagulation factor concentrates market is expected to grow the fastest in the projected period, according to the drug class. Because of increased R&D in this market and pharmaceutical companies’ greater focus on recombinant products.
- Because of the rising prevalence of various blood disorders and increased awareness among the patient population in this area, North America is likely to hold a significant market share in the blood disorder treatment industry. According to the World Federation of Haemophilia, over 18 thousand persons in the United States have hemophilia and over 11 thousand have von Willebrand disease. Haemophilia A affects 1 in every 5,000 male births, and about 400 kids are born with the disease each year. Furthermore, the availability of well-established healthcare infrastructure, as well as rising investments in research and development to produce treatment alternatives for blood disorders, are propelling the regional sector forward.
- The European market, along with North America, accounts for the vast bulk of worldwide market share. It is predicted to grow at an exceptional rate during the projection period. Bayer AG (Germany) and Grifols SA currently have the majority of the European market share (Spain). A working committee on women and bleeding disorders was suggested and approved by the European Association for Haemophilia and Allied Doctors in 2018. This group’s main purpose is to raise awareness among healthcare providers and help them understand the concerns of women who suffer from bleeding problems. During the forecast period, the German bleeding disorders treatment market is expected to lead the European market. Some of the factors assisting the industry’s growth include active initiatives by key market participants to raise awareness and new product releases. As an example, Bayer AG established a three-year collaboration with the Children’s Hospital on December 5, 2001, with the goal of discovering and developing small molecules for Haemophilia A and B.
- The Blood Disorder Therapeutics Market is competitive and fragmented, with a few significant competitors. Few big firms currently dominate the market in terms of market share. Takeda Pharmaceutical Company Limited (Shire Plc), Sanofi, Novo Nordisk A/S, CSL Ltd, Pfizer Inc, Bayer AG, Celgene Corporation, Alexion Pharmaceuticals, Inc, Amgen Inc, and AstraZeneca Plc are some of the firms that are now dominating the market.
- Various strategies, such as product releases and approvals, are used by these players. Mergers, acquisitions, and partnerships are among the many expansion tactics used by these players. Players are gaining market share in the bleeding disorder therapy market by implementing these techniques.
The report can be customized as per the requirements; talk to our team @ https://www.marketdataforecast.com/market-reports/bleeding-disorders-treatment-market/customization
SEGMENTS ANALYZED UNDER THIS REPORT:
By Drug Class:
- Fibrin Sealant
- Recombinant Coagulation Factor Concentrates
- Plasma Derived Coagulation Factor Concentrates
- Hemophilia A
- Hemophilia B
- North America
- Latin America
- Middle East and Africa
BROWSE REGIONAL REPORTS:
- North America Bleeding Disorders Treatment Market
- Europe Bleeding Disorders Treatment Market
- APAC Bleeding Disorders Treatment Market
- Latin America Bleeding Disorders Treatment Market
- MEA Bleeding Disorders Treatment Market
Market Data Forecast is a firm working in market research, business intelligence, and consulting. We have rich research and consulting experience for various business domains to cater to individual and corporate clients’ needs.
Market Data Forecast